Stem Cell Therapy Market Forecast, Industry Developments and Competitive Outlook to 2035

Stem Cell Therapy Market to Reach USD 5.84 Billion by 2035, Growing at a 25.26% CAGR as Allogeneic Therapies and Oncology Lead Demand

Ottawa, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The global stem cell therapy market is projected to grow from USD 613.7 million in 2025 to USD 768.72 million in 2026, reaching approximately USD 5.84 billion by 2035. This represents a compound annual growth rate (CAGR) of 25.26% between 2026 and 2035, according to Towards Healthcare Research & Consulting a sister firm of Precedence Research.

Request a sample of the Stem Cell Therapy Market report, including its coverage and research scope: Download Sample

Growth is being supported by increasing research into regenerative medicine, rising demand for treatments for chronic and degenerative diseases, and progress in cell processing and manufacturing. Oncology remains the leading application, while musculoskeletal disorders, neurological conditions and cardiovascular diseases offer further development opportunities.

Market Definition

Stem cell therapy uses stem cells to repair, replace or regenerate damaged cells and tissues. These cells can develop into different specialized cell types, making them relevant to several areas of medicine.

The market includes the development, manufacturing and use of therapies based on allogeneic and autologous stem cells, hematopoietic stem cells, mesenchymal stem cells and other cell sources. Applications range from established hematopoietic stem cell transplantation to investigational approaches for neurological, cardiovascular and musculoskeletal conditions.

The commercial opportunity extends beyond therapy developers. It also includes cell processing, culture media, expansion technologies, cryopreservation, testing, quality control, specialized storage and contract manufacturing services.

Market Key Takeaways

• The market is forecast to reach USD 5.84 billion by 2035, with a 25.26% CAGR.
• Allogeneic stem cell therapies accounted for 30% of the market by therapy type in 2025.
• Oncology represented 45% of the market by therapeutic application in 2025.
• North America held a 42% regional share in 2025.
• Asia-Pacific is expected to offer significant growth opportunities.
• Autologous therapies and musculoskeletal applications are expected to attract further research and development.
• Manufacturing scale, quality standards and regulatory readiness will remain important factors in commercialization.
  

Arrange a discussion about report coverage, customization or research requirements @ Schedule a Meeting

Market Trends

The industry is moving from laboratory research toward more structured clinical development and manufacturing. Companies are working to improve cell isolation, expansion, differentiation, genetic modification and cryopreservation. These capabilities are important because cell-based products require consistent quality and controlled handling throughout development and delivery.

Manufacturing partnerships are becoming more important. In February 2026, Catalent and S.Biomedics announced a partnership to support development and manufacturing of TED-A9, an allogeneic pluripotent stem-cell-derived therapy being developed for Parkinson’s disease. The collaboration highlights the role of specialized CDMOs in helping developers establish GMP-ready manufacturing for later-stage clinical development.

A further development came in February 2026, when Cellcolabs and the Center for Neuromusculoskeletal Restorative Medicine at InnoHK announced a collaboration supporting a Phase I/II clinical trial of mesenchymal stem cell therapy for knee osteoarthritis. Cellcolabs is contributing GMP-grade MSCs, connecting clinical research with industrial-scale cell production.

The broader cell and gene therapy pipeline also reflects continued clinical activity. The 2026 global regulatory report from the International Society for Cell & Gene Therapy recorded 383 active clinical trials across its cell and gene therapy scope, with Phase I and II studies representing 95% of the pipeline. This figure covers the wider cell and gene therapy field and should not be interpreted as a stem-cell-only trial count.

Market Drivers, Restraints and Opportunities

Clinical evidence remains a key driver, but promising research does not automatically translate into an approved or commercially available treatment. Developers must demonstrate safety, efficacy, manufacturing consistency and an appropriate regulatory pathway. High development costs, reimbursement uncertainty and complex logistics can also delay wider adoption.

Market Segmentations

By Therapy Type

Allogeneic therapies led the market in 2025. Their potential for standardized production and treatment of multiple patients makes them commercially attractive. However, immune compatibility, safety and manufacturing controls remain important considerations. Autologous therapies offer a different value proposition through patient-specific treatment, but their production models can be more complex and costly.

By Therapeutic Application

Oncology held the largest application share. Musculoskeletal disorders are an important opportunity area, supported by research into cartilage, bone, muscle and tissue repair. Neurological applications, including Parkinson’s disease, are also attracting attention as developers investigate stem-cell-derived cell products.

Submit an inquiry about dashboard access and market intelligence requirement @ Explore the Towards Healthcare Dashboard

Market Regional and Country-Level Analysis

North America led the market with a 42% share in 2025. Europe accounted for 25%, while Asia-Pacific represented 20%. The remaining 13% is the combined share for Latin America and the Middle East and Africa, calculated from the reported regional figures.

The United States and Canada benefit from established research and biotechnology ecosystems. Europe offers opportunities through its research institutions and advanced therapy development framework. Asia-Pacific is an important expansion region, particularly as Japan, China, India and South Korea strengthen research, clinical development and manufacturing capabilities.

Company and Competitive Intelligence

The competitive landscape includes therapy developers, biotechnology companies, pharmaceutical firms, research organizations and specialist manufacturing providers.

The 2026 partnerships involving S.Biomedics and Cellcolabs show how developers are combining clinical expertise with external manufacturing capabilities. For investors and business development teams, monitoring clinical milestones, production readiness, partnerships, regulatory progress and manufacturing capacity is becoming as important as tracking company pipelines.

Emerging Market Opportunities

The next stage of market development will depend on the ability to translate clinical research into reproducible and commercially viable treatments. Key opportunity areas include allogeneic cell platforms, iPSC-derived therapies, automated cell expansion, cryopreservation, GMP manufacturing, quality testing and advanced cell characterization.

Companies that can demonstrate reliable production, consistent product quality and a clear regulatory strategy may be better positioned as more therapies move into later-stage clinical development.

How Towards Healthcare Supports Stem Cell Therapy Market Decisions

Towards Healthcare Research & Consulting provides market intelligence and customized research to help companies assess opportunities, monitor competitors and plan commercial strategies.

Continuous Market Intelligence Updates

The stem cell therapy market changes as clinical programs advance, partnerships are announced, manufacturing facilities expand and regulatory requirements develop. Towards Healthcare can support ongoing monitoring through:

• Monthly updates: New company announcements, funding, partnerships, clinical trial activity and product developments.
• Quarterly updates: Competitor benchmarking, pipeline progress, market activity and regional developments.
• Six-monthly updates: Changes in manufacturing capacity, technology adoption, investment patterns and market positioning.
• Annual updates: Market size and forecast revisions, segment performance, country opportunities and long-term competitive analysis.

Fill out the form for relevant samples, case studies, and examples @ sales@towardshealthcare.com

Report and Research Access

• Purchase / Buy Now – Review report licensing options and proceed to purchase.
• Schedule a Meeting – Arrange a discussion about report coverage, customization or research requirements.
• Explore the Towards Healthcare Dashboard – Submit an inquiry about dashboard access and market intelligence requirements.
• Explore the Stem Cell Therapy Market Report – View the market forecast, segments, regional analysis and company coverage.

Related Reports

1. Stem Cell Reconstructive Market
2. Cell Therapy Market
3. Cell and Gene Therapy Services Market
4. U.S. Cell and Gene Therapy Market
5. Autologous Cell Therapy Market
6. Autologous Stem Cell and Non-Stem Cell Therapies Market
7. Cell Therapy Monitoring Kits Market
8. U.S. Advanced Therapy Manufacturing Market
9. Cell and Gene Therapy Predictions for 2026
   

Partner

• Precedence Research
• Towards Packaging
• Towards Chemical and Materials
  

Connect With Us

• USA: +1 804 441 9344
• APAC: +61 485 981 310 | +91 87933 22019 | +65 3105 1271
• Europe: +44 7383 092 044
• Email: sales@towardshealthcare.com

Follow Us

• LinkedIn
• X
• Instagram